1. Home
  2. HOOD vs REGN Comparison

HOOD vs REGN Comparison

Compare HOOD & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Robinhood Markets Inc.

HOOD

Robinhood Markets Inc.

HOLD

Current Price

$113.78

Market Cap

78.6B

Sector

Technology

ML Signal

HOLD

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

HOLD

Current Price

$670.06

Market Cap

68.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HOOD
REGN
Founded
2013
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
78.6B
68.6B
IPO Year
2021
1995

Fundamental Metrics

Financial Performance
Metric
HOOD
REGN
Price
$113.78
$670.06
Analyst Decision
Buy
Buy
Analyst Count
23
25
Target Price
$105.00
$830.16
AVG Volume (30 Days)
29.6M
986.6K
Earning Date
04-28-2026
04-29-2026
Dividend Yield
N/A
0.55%
EPS Growth
31.41
8.19
EPS
0.38
6.75
Revenue
$4,473,000,000.00
$5,872,227,000.00
Revenue This Year
$21.75
$12.45
Revenue Next Year
$19.35
$10.13
P/E Ratio
$309.38
$96.34
Revenue Growth
51.58
20.82
52 Week Low
$63.52
$541.00
52 Week High
$153.83
$821.11

Technical Indicators

Market Signals
Indicator
HOOD
REGN
Relative Strength Index (RSI) 65.60 64.23
Support Level $105.65 $668.85
Resistance Level $122.62 $783.87
Average True Range (ATR) 7.13 15.22
MACD 1.22 8.25
Stochastic Oscillator 78.17 99.63

Price Performance

Historical Comparison
HOOD
REGN

About HOOD Robinhood Markets Inc.

Robinhood is a diversified financial services provider best known for its retail brokerage platform, which historically caters to a young, risk-seeking clientele that trades heavily on margin and in higher-risk asset classes like options, futures, cryptocurrencies, and more recently, in prediction markets. As those customers' financial needs have begun to mature, Robinhood has rolled out a suite of more conventional products, from retirement accounts to high-yield cash sweep accounts to nascent advisory services (Robinhood Strategies). With $322 billion in customer assets and 27 million active accounts at year-end 2025, the firm has emerged as a significant player in the large and quickly growing US brokerage market.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Share on Social Networks: